Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kenvue Inc. Common Stock (NY:KVUE)

17.53 +0.04 (+0.23%)
Official Closing Price Updated: 7:00 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kenvue Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Want Reliable Dividend Income? These 3 Stocks Yield 5% and Have Been Raising Their Payouts for Decades ↗
Via The Motley Fool
News headline image
Billionaire Investor Cuts Tylenol Maker Kenvue Stake By 64% ↗
Daniel Loeb trims major stake in Kenvue as company advances restructuring and prepares for acquisition by Kimberly-Clark. 
Via Benzinga
News headline image
Kenvue to Announce First Quarter 2026 Results on May 7, 2026
From Kenvue
Via Business Wire
News headline image
Here's What to Expect From Kenvue's Next Earnings Report
Kenvue will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth. 
Via Barchart.com
Topics ETFs
News headline image
The Smartest Dividend Stocks to Buy With $2,000 Right Now ↗
Growth stocks may be on fire again, but if you needed dividend stocks then, you still need them now. Here's a look at three of the best bets at this time. 
Via The Motley Fool
News headline image
Meet the Dividend King That Just Raised Its Payout For the 70th Consecutive Year. Here's Why It's a No-Brainer Buy Before the End of April. ↗
Decades of dividend increases and a 3% yield make Procter & Gamble a passive-income powerhouse. 
Via The Motley Fool
Topics Economy
News headline image
3 Healthcare Stocks That Have Held Up in Every Market Downturn ↗
Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns. 
Via The Motley Fool
Topics Economy
News headline image
Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now ↗
Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation 
Via MarketBeat
Topics Bonds Earnings Economy
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
This Value Stock Yields 5.3% and Has Paid a Dividend for 92 Consecutive Years. Here's Why It's a Buy in April. ↗
Kimberly Clark is a worthy foundational holding in a passive-income portfolio. 
Via The Motley Fool
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone
NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,... 
Via Finterra
Topics Artificial Intelligence Death Economy
News headline image
Better Buy Right Now: Johnson & Johnson Vs. Pfizer ↗
The choice is based on more than just the dividend payout. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
4 Stocks That Can Fund Decades of Passive Income -- Buy Them While They're Down ↗
These defensive consumer stocks are flashing buy signals while the market chases AI hype. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Wall Street's Great Rotation: Goldman and JPMorgan Pivot to 'Innovation Supercycle' as Interest Income Peaks
As the sun sets on the era of easy profits from elevated interest rates, the titans of Wall Street are preparing to unveil a new chapter in their growth stories. For the first time in three years, the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Could Buying This Dividend Pharma Stock Today Set You Up for Life? ↗
This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index. 
Via The Motley Fool
Topics Stocks
News headline image
The Great Consolidation: Q1 2026 M&A Activity Shatters Records Amid $3 Trillion Private Equity Surge
The global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Looks Like M&A Week in 3 Different Sectors ↗
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry. 
Via The Motley Fool
News headline image
These 3 Beaten-Down Stocks Haven't Been This Cheap in Over a Decade ↗
Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns. 
Via The Motley Fool
Topics Economy World Trade
News headline image
Wall Street's Advisory Windfall: Goldman Sachs and JPMorgan Lead the M&A Renaissance
The first quarter of 2026 has officially marked the end of the deal-making drought, ushering in a lucrative "advisory windfall" for Wall Street’s elite investment banks. Driven by a surge in... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
This Healthcare Stock Barely Flinches During Market Sell-Offs ↗
Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%. 
Via The Motley Fool
Topics Economy Stocks
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
The Great Divergence: Q1 2026 M&A Hits Record $813.3 Billion Amidst "K-Shaped" Recovery
As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Breathing Easy: Prestige Consumer Healthcare Inks $1.045 Billion Deal to Acquire Breathe Right and Expansion Portfolio
In a move that signals a bold return to aggressive brand acquisition, Prestige Consumer Healthcare Inc. (NYSE: PBH) announced on March 20, 2026, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy
News headline image
2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow ↗
This stock is one to own during any market environment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Dividend Stocks to Double Up on Right Now ↗
Capitalize on near-term bearishness with these two high-quality dividend stocks. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape
In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health... 
Via MarketMinute
Topics Artificial Intelligence Lawsuit
News headline image
How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?
While recent performance trails the industry, Kenvue continues to retain measured analyst confidence and long-term relevance. 
Via Barchart.com
Topics ETFs
News headline image
My Top 3 Dividend Kings to Buy for March 2026 ↗
These Dividend Kings offer price appreciation potential alongside dividend growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.